145 related articles for article (PubMed ID: 25076325)
1. Pharmacogenetics in neuroendocrine tumors of the pancreas.
Rizvi SM; Wong J; Saif MW; Jia Y
JOP; 2014 Jul; 15(4):299-302. PubMed ID: 25076325
[TBL] [Abstract][Full Text] [Related]
2. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
3. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G
Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792
[TBL] [Abstract][Full Text] [Related]
4. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
[TBL] [Abstract][Full Text] [Related]
5. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
6. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
7. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
de Wilde RF; Edil BH; Hruban RH; Maitra A
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
[TBL] [Abstract][Full Text] [Related]
8. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
Liu IH; Ford JM; Kunz PL
Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
10. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
13. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
Wiedenmann B; Pavel M; Kos-Kudla B
Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
[TBL] [Abstract][Full Text] [Related]
14. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
15. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merika E; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
[TBL] [Abstract][Full Text] [Related]
17. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
[TBL] [Abstract][Full Text] [Related]
19. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for GI and pancreatic NETs].
Doi T
Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
